Mucinex Tablet, Extended Release
NDC Package 72854-223-20
Package Information
Mucinex (naproxen sodium, pseudoephedrine hydrochloride) tablets is uses temporarily relieves these cold, sinus, and flu symptoms: ■ sinus pressure ■ minor body aches and pains ■ headache ■ nasal and sinus congestion (promotes sinus drainage and restores freer breathing through the nose) ■ fever. This formulation utilizes a tablet, extended release delivery system. Marketed by Reckitt Benckiser Llc, this product is identified by NDC 72854-223 and is authorized under FDA application ANDA076518.
Identification & Billing
- RxCUI: 1367426 - naproxen sodium 220 MG / pseudoephedrine HCl 120 MG 12HR Extended Release Oral Tablet
- RxCUI: 1367426 - 12 HR naproxen sodium 220 MG / pseudoephedrine hydrochloride 120 MG Extended Release Oral Tablet
- RxCUI: 1367426 - naproxen sodium 220 MG / pseudoephedrine hydrochloride 120 MG 12 HR Extended Release Oral Tablet
Clinical Specifications
- Adrenergic alpha-Agonists - [MoA] (Mechanism of Action)
- Anti-Inflammatory Agents, Non-Steroidal - [CS]
- Cyclooxygenase Inhibitors - [MoA] (Mechanism of Action)
- Nonsteroidal Anti-inflammatory Drug - [EPC] (Established Pharmacologic Class)
- alpha-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 72854 - Reckitt Benckiser Llc
- 72854-223 - Mucinex
- 72854-223-20 - 2 BLISTER PACK in 1 CARTON / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
- 72854-223 - Mucinex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72854-223-20 identifies a specific commercial package of 2 blister pack in 1 carton / 10 tablet, extended release in 1 blister pack of Mucinex Ds 12hr Cold, Fever And Sinus, a human over the counter drug labeled by Reckitt Benckiser Llc. This tablet, extended release is formulated for oral use and contains naproxen sodium; pseudoephedrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Reckitt Benckiser Llc on July 01, 2026. The current certification is valid through December 31, 2027.
How is this Reckitt Benckiser Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72854022320. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.